Phase II Trial of Sorafenib in Combination With Modified FOLFOX in Patients With Advanced Hepatocellular Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2018
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 23 Apr 2018 Planned End Date changed from 1 May 2017 to 1 Dec 2018.
- 23 Apr 2018 Planned primary completion date changed from 1 May 2017 to 1 Jul 2018.
- 23 Apr 2018 Status changed from recruiting to active, no longer recruiting.